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Abstract
Background: Although myocardial infiltration with leukemic blasts is a known finding in patients
with acute leukemia, this phenomenon in myelodysplasia is not reported in the literature. Cardiac
symptoms in patients with myelodysplasia are often due to anemia and may be due to iron overload
and side effects of therapy.
Case presentation: Herein we report the first case of neoplastic infiltration of the heart with
associated myocardial necrosis in a patient with myelodysplasia. It was associated with unicellular
and multifocal geographic areas of necrosis in the left ventricle and the interventricular septum. It
is likely that cardiac compromise in our patient was due to a combination of restrictive
cardiomyopathy due to leukemic infiltration, concomitant anemia, cardiac dilatation, conduction
blocks and myocardial necrosis. Myocardial necrosis was most likely due to a combination of
ischemic damage secondary to anemia and prolonged hypotension and extensive leukemic
infiltration. Markedly rapid decrease in ejection fraction from 66% to 33% also suggests the role of
ischemia, since leukemic infiltration is not expected to cause this degree of systolic dysfunction
over a 24-hour period. The diagnosis was not suspected during life due to concomitant signs and
symptoms of anemia, pulmonary infections, and pericardial and pleural effusions. The patient
succumbed to cardiac failure.
Conclusion: Hemopoietic cell infiltration was not considered in the differential diagnosis and
contributed to this patient's morbidity and mortality. This case highlights the clinical importance of
considering myocardial infiltration in patients with myelodysplasia and cardiac symptoms.
Background
Myelodysplastic syndromes are hematologic malignan-
cies characterized by dyspoiesis, a progressive clinical
course and usually a fatal outcome due to either transfor-
mation to acute leukemia or bone marrow failure [1,2].
The patients often present with symptoms attributable to
cytopenias and the clinical course reflects progression to
bone marrow failure or transformation to acute leukemia
[3]. The patients usually managed with supportive care
and sometimes novel treatments [4] are monitored for
evolution to acute leukemia and progressive marrow fail-
ure using some risk stratification scheme, for instance the
International Prognostic Scoring System [5].
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Cardiac symptoms in patients with myelodysplasia are
usually due to anemia [6] or iron overload [7] and some-
times due to toxic effects of drug treatment. The latter
include cardiac arrythmias due to a hemopoietic growth
factor, IL-11 [8], bradycardia and orthostasis due to
immunomodulating thalidomide [9], exacerbation of
congestive cardiac failure due to immunomodulating inf-
liximab [10], cytotoxic chemotherapy e.g. cytarabine
related cardiotoxicity [11], and conduction abnormalities
due to a putative differentiating agent arsenic trioxide
[12]. Although infiltration by leukemic blasts is a known
phenomenon in patients with acute leukemia [13-15], to
the best of our knowledge our's is the first case report of
cardiac infiltration by malignant hemopoietic cells in a
patient with myelodysplasia. The extensive hemopoietic
cell infiltration was not considered in the differential diag-
nosis and contributed to this patient's morbidity and
mortality. This case, therefore, highlights the importance
of considering this phenomenon in patients with myelo-
dysplasia who develop cardiac symptoms.
Case presentation
A 64-year-old woman with increased lethargy, generalized
weakness, and shortness of breath on exertion was found
to have pancytopenia on a routine blood count; hemo-
globin 80 g/L, white blood cells 3.2 × 109/L, platelets 98 ×
109/L. After bone marrow examination a diagnosis of
refractory anemia with excess blasts (RAEB) was made.
The symptoms were attributed to anemia and she received
5 units of packed red cells.
Approximately 2 months later, she developed a 4-day
course of intermittent chills and sweating but was afebrile
when she came to the local emergency department. The
CBC at admission demonstrated 6.9 × 109/L white blood
cells with left shift and 0.21 × 109/L blasts, 76 g/L hemo-
globin and 65 × 109/L platelets. During her hospital stay
the white blood cells increased to 16.9 × 109/L with
increasing left shift; anemia and thrombocytopenia per-
sisted. There was central bronchial wall thickening and
interstitial prominence in the chest radiograph suggestive
of an early viral infectious process. The cardiomediastinal
silhouette was within normal limits (Figure 1a). The elec-
trocardiogram (ECG) showed normal sinus rhythm. The
patient was started on oral levofloxacin.
Four days later, the patient became febrile (38.8 degrees)
and developed increasing shortness of breath and retros-
ternal chest pain that radiated to both arms. There were
bilateral crepitations and decreased breath sounds. Repeat
chest radiograph demonstrated bilateral pleural effusions,
basal consolidation of the left lower lobe and left ven-
tricular enlargement. There was no evidence of cardiac
failure (Figure 1b). Right bundle branch block (RBBB)
with sinus tachycardia was identified on ECG. An echocar-
diographic study identified a moderate pericardial effu-
sion with no cardiac tamponade; the left ventricular
ejection fraction was 66% and there were no regional wall
motion abnormalities. The next day, a repeat echocardio-
graphic study identified a 33% ejection fraction with left
ventricular global hypokinesia and a moderate sized peri-
cardial effusion without tamponade. The patient was
treated for pneumonia, hypotension, acute renal failure,
and anemia but developed heart block and cardiorespira-
tory compromise. Her condition deteriorated rapidly and
she died five days post-admission.
Peripheral blood and bone marrow, ante-mortem (Fig-
ures 2, 3, 4, 5): In the peripheral blood there was dysplasia
in the leukocytes (pseudo Pelger-Huet cells and hypogran-
ular neutrophils), platelets (hypogranular platelets and
large platelets) and red cells (macrocytic red cells and
dimorphic red cells) was associated with a left shift and
circulating blasts. The bone marrow was hypercellular
with trilineage dysplasia (pseudo Pelger-Huet cells, eryth-
roid precursors with nuclear bridging, irregular nuclear
contours, irregular hemoglobinization of the cytoplasm
and mononuclear and multinucleated megakaryocytes).
There was abnormal localization of immature precursors
(ALIP) in the core biopsy. The bone marrow aspirate dif-
ferential count (table 1) showed increased blasts (18.2%)
while the erythroid precursors were less than 50% of the
nucleated cells.
Post-mortem examination was limited to heart and lungs
at the request of the family. The heart lay free in the peri-
cardial sac, surrounded by 300 mL of straw-colored peri-
cardial effusion. There was fibrinous pericarditis. The free
wall of the left ventricle and the interventricular septum
had soft and hemorrhagic areas scattered throughout,
with no definite transmural focus. The major coronary
arteries (right coronary, left anterior descending, and left
circumflex arteries) were involved to only a minor degree
by old eccentric atherosclerotic plaques (maximum steno-
sis of 25 to 30%) with no evidence of an acute event
(thromboembolus, hemorrhage, rupture). There was
bilateral pulmonary edema and left lower lobe congestion
and consolidation.
Microscopic examination of the heart (Figures 6, 7, 8, 9)
revealed a diffuse interstitial infiltrate of immature dys-
plastic hemopoietic cells involving the myocardium,
endocardium and the pericardium. Cells of myeloid,
erythroid and megakaryocytic lineages were present.
These infiltrates were associated with single fibre myocyte
necrosis as well as larger foci of necrosis. A majority of
these cells were immunopositive for myeloperoxidase
consisted with myeloid lineage.BMC Blood Disorders 2006, 6:4 http://www.biomedcentral.com/1471-2326/6/4
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Pancytopenia associated with peripheral blood features
including dysplastic changes in the granulocytes, <1%
blasts and < 1 × 109/L monocytes coupled with multilin-
eage dysplasia and 18.2% blasts in the bone marrow was
in keeping with the diagnosis of refractory anemia with
excess blasts-2 (RAEB-2) [1]. Clinical presentation and
clinical course of RAEB is typically related to the symp-
Bone marrow aspirate with marked erythroid dysplasia  (Giemsa × 500) Figure 3
Bone marrow aspirate with marked erythroid dysplasia 
(Giemsa × 500).
Plain radiographs of the chest (PA views) at admission (a) and four days later (b) with noticeable increase in the cardiac silhou- ette Figure 1
Plain radiographs of the chest (PA views) at admission (a) and four days later (b) with noticeable increase in the cardiac silhou-
ette.
Peripheral blood smear with a circulating blast and a pseudo  Pelger-Huet cell, (Giemsa × 500) Figure 2
Peripheral blood smear with a circulating blast and a pseudo 
Pelger-Huet cell, (Giemsa × 500).BMC Blood Disorders 2006, 6:4 http://www.biomedcentral.com/1471-2326/6/4
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toms of decreased counts of one or more cell lineages and
blast count [3,4]. The symptoms of lethargy, shortness of
breath, and generalized weakness in this patient may be
attributed to both anemia and cardiac infiltration by
malignant cells, although the former is much more com-
mon clinically [6]. Her cardiac symptoms were not due to
drugs sometimes used in patients with myelodysplasia,
since the patient had not received cytotoxic, immu-
nomodulatory, putative differentiating agent, or hemo-
poietic growth factor therapy [8-12].
Although cardiac involvement in leukemic extramedul-
lary spread is relatively common (ranging from 37–44%)
[13-15], clinical signs are found in less than 1% of cases
[16-18] and leukemic cardiac involvement antemortem is
usually not suspected [19]. The most likely reason for this
is the subclinical nature of the symptoms and signs in car-
diac leukemic infiltration [20]. This is in keeping with the
observation that gross infiltrative disease at the time of
initial diagnosis in patients with acute leukemia is rare
[14,19,21]. In the patient reported here extramedullary
(cardiac) infiltration by dysplastic hemopoietic precursors
by itself is not a reason to upgrade the diagnosis to acute
leukemia. Extramedullary infiltration at other sites has
been reported in patients with myelodysplastic syn-
dromes [22,23], more frequently in patients with chronic
myelomonocytic leukemia compared to RAEB and refrac-
tory cytopenia with multilineage dysplasia [23,24].
Although it may herald transformation to acute leukemia
[25], this transformation may not be observed for some
time [26,27] and sometimes not at all during follow-up
[28,29]. Granulocyte-macrophage colony stimulating fac-
tor overproduction may lead to autonomous colony for-
mation in the bone marrow of patients with
myelodysplastic syndrome [30]; this may partially explain
proliferation of malignant hemopoietic cells in the heart
infiltrated by malignant cells.
Although cardiac infiltration is usually associated with
high WBC count (mostly due to blasts) and advanced dis-
ease [14], the presence of a high circulating white blood
cell count is not a necessity for developing cardiac infiltra-
tion as infiltration has been shown to be present in
aleukemic leukemia [21] as well as in patients with very
low white cell counts [31]. The development of cardiac
infiltration in our patient with myelodysplasia and pancy-
topenia would be consistent with this observation keep-
ing with this pheneomenon; the rising white late in the
course of the disease was was predominantly due to neu-
trophilia and left shift and not due to a large blast popu-
lation.
The effects of hemopoietic cell infiltrate in the heart are
varied. Leukemic deposits may form mass lesions [32] or
thrombi [33]. Pericardial involvement may lead to peri-
cardial effusion contributing to restrictive myocardial dys-
function [19,34]. Reports of heart block in extramedullary
cardiac leukemic involvement are few [31,35,36]. Heart
block has been observed in patients with both very high
and very low peripheral blood white cell counts [31] and
may be reversible after local radiotherapy to the heart
despite persistence of leukemic infiltration [31]. However,
infiltration of the conduction system is a potentially seri-
ous complication that may be fatal [37]. Leukemic infil-
tration is a rare cause of restrictive cardiomyopathy [18].
An antemortem study of 18 patients with acute leukemia
Bone marrow core biopsy with abnormal localization of  immature precursors (H&E × 300) Figure 5
Bone marrow core biopsy with abnormal localization of 
immature precursors (H&E × 300).
Bone marrow core biopsy with megakaryocytic and eryth- roid dysplasia (H&E × 300) Figure 4
Bone marrow core biopsy with megakaryocytic and eryth-
roid dysplasia (H&E × 300).BMC Blood Disorders 2006, 6:4 http://www.biomedcentral.com/1471-2326/6/4
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(6 ALL, 12 AML) demonstrated no significant difference
from controls in LV systolic function parameters includ-
ing LV ejection fraction, similar to what was observed in
our patient at initial echocardiography [18]. However, LV
diastolic dysfunction has been observed in 38 percent of
leukemic patients, independent of age and heart rate. It is
likely that cardiac compromise in our patient was due to
a combination of restrictive cardiomyopathy due to leuke-
mic infiltration, concomitant anemia, cardiac dilatation,
conduction blocks and myocardial necrosis. Myocardial
necrosis was most likely due to a combination of, a)
ischemic damage secondary to anemia and prolonged
hypotension and b) extensive leukemic infiltration. Mark-
edly rapid decrease in ejection fraction from 66% to 33%
also suggests the role of ischemia, since leukemic infiltra-
tion is not expected to cause this degree of systolic dys-
function over a 24-hour period.
Usual causes of death in patients with myelodysplasia are
related to bone marrow failure and transformation to
acute leukemia [3,4,38], however, in this patient, death
was attributed to cardiac failure. It is likely that the rising
white blood cell count during second admission,
although predominantly due to neutrophilia and left
shift, was associated with early transformation- in view of
increased peripheral blood blast percentage – the limited
autopsy did not permit evaluation of the bone marrow.
Cardiac involvement in by malignant hemopoietic cells is
of more than just academic interest, since cardiac function
has been shown to improve following therapy directed
against malignant infiltrate [31,39]. Incorrect diagnosis
during life and the fatal outcome highlight the clinical
importance of considering myocardial infiltration in
patients with myelodysplasia and cardiac symptoms.
Conclusion
Infiltration of heart tissues by malignant hemopoietic
cells can occur in patients with myelodysplasia. This case
highlights that in a patient with myelodysplasia, leukemic
cardiac infiltration should be considered in the differen-
tial diagnoses when investigating cardiac symptoms and
signs, particularly heart block.
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Extensive septal and intercellular myocardial infiltration with  vascular wall andmyocardial necrosis (H&E × 50) Figure 7
Extensive septal and intercellular myocardial infiltration with 
vascular wall andmyocardial necrosis (H&E × 50).
Table 1: Differential count of the bone marrow aspirate and peripheral blood; total peripheral blood leukocyte count = 3.2 × 109/L.
Specimen Bl Pr My Meta Band Gr Ly Mo Ery
Bone marrow (in %) 18.2 19 24.8 6.0 5.0 1.0 4.5 0.5 21
Peripheral blood (in absolute count, × 109/L) 0.03 0.13 0.11 0 0.19 0.35 2.36 0.03 No nucleated erythroid precursors
Bl: Blasts, Pr: Promyelocytes, My: Myelocytes, Meta: Metamyelocytes, Band: band forms, Gr: Granulocytes, Ly; Lymphocytes, Mo: Monocytes, Ery: 
Erythroid precursors
Epicardial involvement by hemopoietic precursors with fibri- nous pericarditis (H&E × 50) Figure 6
Epicardial involvement by hemopoietic precursors with fibri-
nous pericarditis (H&E × 50).BMC Blood Disorders 2006, 6:4 http://www.biomedcentral.com/1471-2326/6/4
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